MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
PHR stock logo

PHR

Phreesia, Inc.

$8.37
-0.03
 (-0.36%)
[ms_data_label text=’Delayed data’]
Exchange:  NYSE
Market Cap:  504.602M
Shares Outstanding:  1.539M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Healthcare Information Services
   
CEO:  Chaim Indig
Full Time Employees:  2082
Address: 
434 Fayetteville Street
Wilmington
NC
27601
US
Website:  https://www.phreesia.com
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients’ mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company’s Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/28 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202420252026
Revenue356,299419,813480,591
Gross Profit232,288284,879294,445
EBITDA-102,945-25,57829,466
Operating Income-136,479-58,0972,611
Net Income-136,885-58,5272,306

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202420252026
Total Assets370,326388,415663,790
Total Liabilities118,877123,607326,583
Total Stockholders Equity251,449264,808337,207
Total Debt11,98317,80393,224
Cash and Cash Equivalents87,52084,22073,830

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202420252026
Operating Cash Flow-32,37832,38178,814
Capital Expenditure-25,097-24,089-11,101
Free Cash Flow-57,4758,29267,713
Net Income-136,885-58,5272,306
Net Change in Cash-89,163-3,3000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2031Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)539,064.012Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)566,723.985Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)552,000Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)261,922.609Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)275,362.149Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)268,207.999Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)56,043.972Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)59,809.919Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)57,805.186Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)337,294.866Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)354,601.840Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)345,388.974Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.940Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.970Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.910Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)3Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
419.813M  ?P/S
 (TTM)
: 
1.16
?Net Income
 (TTM)
: 
-58527000  ?P/E
 (TTM)
: 
237.55
?Enterprise Value
 (TTM)
: 
585.816M  ?EV/FCF
 (TTM)
: 
9.18
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.01  ?ROIC
 (TTM)
: 
0
?Net Debt
 (TTM)
: 
-66417000  ?Debt/Equity
 (TTM)
: 
0.3
?P/B
 (TTM)
: 
1.62  ?Current Ratio
 (TTM)
: 

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate PHR Intrinsic Value

Common questions about PHR valuation

Is PHR (PHR) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for PHR (PHR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is PHR a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PHR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is PHR’s P/E ratio?

You can see PHR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for PHR?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is PHR a good long-term investment?

Whether PHR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

PHR

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

-0.36
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phreesia, Inc. - PHR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phreesia, Inc.  - PHR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phreesia, Inc. - PHR
Rosen Law Firm Encourages Phreesia, Inc. Investors to Inquire About Securities Class Action Investigation – PHR
PHR Investor Alert: Phreesia Securities Fraud Investigation - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing To Fully Disclose Weakening Revenue Visibility: Levi & Kor
Phreesia: Market Delivers A Resounding Vote Of No Confidence (Rating Downgrade)

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read